Suggestions
Maneesh Jain
CEO & Co-founder at Mirvie
Maneesh Jain is a highly accomplished professional with a strong educational background and extensive experience in the fields of applied physics and biosciences. He holds a Doctor of Philosophy (PhD) in Applied Physics from Stanford University and a BSc in Physics and Electrical Engineering from Caltech. Throughout his career, Jain has held key leadership positions in various organizations, showcasing his expertise in business development, marketing, and research and development programs.
Highlights
The maternal health crisis raging through America is not going to end anytime soon without serious changes. Thank you Reuters and Amina N. for shining a light on this critical topic and the outstanding opportunity for investment, innovation and impact. It shocks so many people to hear that pregnancy is more dangerous today than it was 20 years ago. That is absolutely unacceptable, and as Khosla Ventures' Alex Morgan said to Reuters, "Saving the lives of mothers and babies is in everyone's interest."
KV's strategy on investing in maternal health technologies vs. clinics will be an integral part of solving the maternal health crisis. Breakthroughs in biological innovation and tech like Mirvie's #RNA platform can help reverse the tide of this crisis, in concert with novel approaches to maternal care.
Let's not let this article, and moment, pass by without action. There is a compelling, untapped opportunity for investors to prioritize funding maternal health technologies and breakthroughs; for entrepreneurs and founders to become part of the solution; and for researchers to push forward the frontiers of our limited knowledge of maternal health.
The maternal mortality crisis is also a major driver of infant mortality. The health of babies is dually impacted when an expecting mom is diagnosed with a life-threatening pregnancy complication. It’s disheartening to continually see dismal health trends. A new Centers for Disease Control and Prevention report found infant mortality rates in the U.S. increased by 3% in 2022, the first significant rise in two decades.
The status quo isn’t working. With rates of preeclampsia on the rise - which is a leading cause of preterm birth - and preterm birth is a leading cause of infant death, something has to change. Women and babies deserve better.
We need to understand why this is happening and how we can act sooner to protect the lives and health of expecting moms and their babies. This is the crux of what we’re doing Mirvie - tapping into the biology of each pregnancy by using RNA to predict the risk of complications like preeclampsia. This allows pregnant women and their care teams to put a preventive action plan in place before a complication becomes a crisis.
This first-of-its-kind clarity provides an opportunity to intervene early to prevent or mitigate preeclampsia and usher in a new standard of care in #pregnancyhealth, tackling the maternal and infant health crisis head-on.
